Research Article
Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation
Table 1
Baseline demographic and clinical characteristics.
| | Baseline characteristics | Normal responder (n = 64) | Sensitive responder (n = 422) | Highly sensitive responder (n = 40) | P |
| | Male sex, n (%) | 37 (57.81%) | 230 (54.50%) | 22 (55%) | 0.88 | | Age, mean ± SD | 58.91 ± 9.94 | 60.94 ± 11.08 | 60.52 ± 12.33 | 0.41 |
| | Comorbidities | | Hypertension, n (%) | 27 (42.18%) | 168 (39.81%) | 14 (35%) | 0.76 | | Hypercholesterolemia, n (%) | 13 (20.31%) | 55 (13.03%) | 6 (15%) | 0.30 | | Diabetes, n (%) | 10 (15.62%) | 48 (11.37%) | 7 (17.5%) | 0.38 | | Previous stroke, n (%) | 12 (18.75%) | 60 (14.22%) | 3 (7.5%) | 0.28 | | Coronary artery disease, n (%) | 23 (35.94%) | 100 (23.70%) | 11 (27.5%) | 0.11 | | Peripheral arterial disease, n (%) | 7 (10.94%) | 64 (15.17%) | 3 (7.5%) | 0.31 | | Hepatic impairment, n (%) | 2 (3.12%) | 22 (5.21%) | 2 (5%) | 0.61 | | Renal impairment, n (%) | 10 (15.62%) | 32 (7.58%) | 5 (12.5%) | 0.08 | | Valvular heart disease, n (%) | 28 (43.75%) | 180 (42.65%) | 17 (42.5%) | 0.99 | | Tobacco, n (%) | 8 (12.5%) | 76 (18.01%) | 7 (17.5%) | 0.58 | | Alcoholic, n (%) | 8 (12.5%) | 63 (14.93%) | 6 (15%) | 0.88 |
| | Medications during follow-up | | Amiodarone, n (%) | 15 (23.44%) | 87 (20.62%) | 8 (20%) | 0.87 | | Antiplatelets, n (%) | 7 (10.94%) | 25 (5.92%) | 2 (5%) | 0.30 | | Digoxin, n (%) | 20 (31.25%) | 123 (29.15%) | 9 (22.5%) | 0.61 | | Beta-blockers, n (%) | 21 (32.81%) | 112 (26.54%) | 9 (22.5%) | 0.46 | | Calcium channel blockers, n (%) | 18 (28.12%) | 93 (22.04%) | 10 (25%) | 0.53 | | CHA2DS2-VASc score, mean ± SD | 2.28 ± 1.74 | 2.23 ± 1.52 | 1.93 ± 1.27 | 0.45 | | HAS-BLED score, mean ± SD | 1.70 ± 1.23 | 1.57 ± 1.19 | 1.38 ± 1.25 | 0.40 | | Average TTR | 64.04 ± 19.42 | 69.88 ± 18.18 | 66.92 ± 18.89 | 0.22 |
|
|
SD, standard deviation; TTR, time in therapeutic range. |
